alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › lecanemab-therapy

lecanemab-therapy

3 studies tagged lecanemab-therapy, dated 2026-01-01 to 2026-10-11. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Baseline Physical Frailty Predicts Clinical Outcomes During Lecanemab Therapy in Early Alzheimer's Disease: A Prospective Real-World Cohort Study 2026-10-11
  2. Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181 2026-08-28
  3. Six-month follow-up of ARIA-H and iron deposition in real-world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort 2026-01-01

Studies

3 studies carry this tag.

Date range

2026

Top journals

  • Aging and disease 1
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • The journal of prevention of Alzheimer's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Baseline Physical Frailty Predicts Clinical Outcomes During Lecanemab Therapy in Early Alzheimer's Disease: A Prospective Real-World Cohort Study

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Aging and disease 2026-10-11 Treatments

    Baseline SPPB-defined physical frailty was associated with longitudinal clinical progression and IRRs during lecanemab treatment.

  2. Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. The journal of prevention of Alzheimer's disease 2026-08-28 Treatments

    This real-world study evaluated the long-term feasibility of lecanemab treatment in 117 patients with early Alzheimer's disease at Kanazawa University Hospital.

  3. Six-month follow-up of ARIA-H and iron deposition in real-world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-01-01 Treatments

    7T MRI provides superior ARIA-H detection and iron dynamics monitoring, supporting its role in risk stratification and therapy assessment for lecanemab-treated patients.

All topic tags with their study counts